Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abbott Laboratories ( (ABT) ) has provided an update.
Abbott Laboratories, a global healthcare leader in diagnostics, medical devices, nutritionals and branded generics, has expanded its portfolio with a strong emphasis on cancer screening and precision oncology diagnostics. By integrating Exact Sciences’ flagship tests, Abbott gains a comprehensive suite of tools for early cancer detection and personalized treatment decisions in the fast‑growing U.S. cancer diagnostics market.
On March 23, 2026, Abbott completed its acquisition of Exact Sciences for $105 per share in cash, making Exact a wholly owned subsidiary and ending its Nasdaq trading on March 20, 2026. The deal establishes Abbott as a leader in the roughly $60 billion U.S. cancer screening and precision oncology segments, adding Cologuard, Oncotype DX, Oncodetect and Cancerguard to its offerings and creating a new growth vertical that is expected to strengthen its positioning in preventative, predictive and personalized diagnostics.
The most recent analyst rating on (ABT) stock is a Buy with a $158.00 price target. To see the full list of analyst forecasts on Abbott Laboratories stock, see the ABT Stock Forecast page.
Spark’s Take on ABT Stock
According to Spark, TipRanks’ AI Analyst, ABT is a Neutral.
The score is driven primarily by solid underlying financial performance (especially strong free cash flow) and favorable earnings-call guidance around continued growth and margin expansion. These positives are offset by weak technical momentum and a relatively expensive valuation, with additional uncertainty from incomplete 2025 balance sheet data and the large debt financing tied to the acquisition.
To see Spark’s full report on ABT stock, click here.
More about Abbott Laboratories
Abbott Laboratories is a global healthcare company with leading businesses in diagnostics, medical devices, nutritionals and branded generic medicines. Headquartered in Illinois, it employs about 122,000 people and serves patients in more than 160 countries, focusing on life‑changing technologies that support health across all stages of life.
Average Trading Volume: 10,983,266
Technical Sentiment Signal: Sell
Current Market Cap: $183.3B
For detailed information about ABT stock, go to TipRanks’ Stock Analysis page.